Introduction
The 2008 revised WHO category of myeloproliferative neoplasms (MPNs) includes systemic mastocytosis (Table 1) [1] . Systemic mastocytosis constitutes a stem cell-derived clonal myeloproliferation with overt mast cell proliferation. Clinical manifestations include urticaria pigmentosa and mast cell mediator release symptoms (MCMRS) such as presyncope, anaphylaxis, and diarrhea [2 ] . Other disease manifestations include osteopenia, hepatosplenomegaly, and abnormalities of blood and bone marrow. Diagnosis requires bone marrow examination including immunohistochemical stains for mast cell tryptase or CD117 (KIT) (Fig. 1 ). More sensitive techniques to detect clonal mast cells include immunophenotyping for CD25 or mutation screening for KIT D816V.
Molecular pathogenesis
Activating mutations of KIT are highly prevalent in systemic mastocytosis; recent information suggests that a significant proportion may harbor mutations in the TET2 (TET oncogene family member 2) gene. KIT mutations In 1993, a mutant KIT allele with two point mutations was described in a human mast cell leukemia (MCL) cell line (HMC-1): a juxtamembrane V560G and a kinase domain D816V [3] . KITD816V or other KIT mutations have since been demonstrated in virtually all patients with systemic mastocytosis [4] . Transgenic mice expressing KITD816V restricted to their mast cells display a systemic mastocytosis phenotype similar to that seen in humans [5] . In murine primary hematopoietic cells [6] , expression of KITD816V induced differentiation into mast cells in the presence of stem cell factor [6]. Similarly, KITD816V, but not the wild-type allele, induced mast cell cluster formation but did not promote factor independence or tumorigenicity in interleukin (IL)-3-dependent BaF3 cells [7] . These observations suggest that KITD816V might be sufficient to cause TET oncogene family member 2 mutations TET2 is a putative tumor suppressor gene located at chromosome 4q24. TET2 mutations were first described in patients with JAK2V617F-positive MPN [8] . Subsequently, the same mutations were found in JAK2V617Fnegative MPN [9] .
TET2 mutations have since been described in other myeloid malignancies including systemic mastocytosis, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [10 ,11,12] . Mutational frequency in systemic mastocytosis was approximately 29%, and the presence of TET2 mutations in systemic mastocytosis was associated with monocytosis. In this preliminary study, TET2 mutations co-segregated with KITD816V and did not appear to affect survival in systemic mastocytosis.
Classification, clinical features and prognosis
Systemic mastocytosis was initially classified into 'benign' and 'malignant' variants [13] [14] [15] [16] . In 1988, Mayo Clinic investigators proposed a more intricate classification system: indolent systemic mastocytosis (ISM); systemic mastocytosis with associated hematological disorders (SM-AHD); ASM; and MCL [17] . In 2001, the WHO refined and formalized this classification system ( Fig. 1) [18] . Although the WHO proposal has been widely adopted in clinical practice, it was not systematically validated by primary data. This was recently accomplished by a Mayo Clinic study [2 ] of 342 adult patients with systemic mastocytosis diagnosed over a 30-year period spanning from 1976 to 2007. Clinical and laboratory features at diagnosis, survival data, and progression to leukemia were documented, and systemic mastocytosis was subclassified according to the 2001 WHO proposal [19] .
Indolent systemic mastocytosis
ISM comprised the largest subgroup and was represented by 159 (46%) patients [2 ,20 ] . Compared with patients with ASM or systemic mastocytosis with associated clonal hematological nonmast cell lineage disease (SM-AHNMD), ISM patients presented with younger age (median 49 years) and a higher prevalence (66-75%) of urticaria pigmentosa-like skin lesions, MCMRS and gastrointestinal symptoms. The WHO system recognizes two provisional ISM subvariants: smoldering systemic mastocytosis (SSM) and isolated bone marrow mastocytosis (BMM) [21] . SSM was characterized by a higher burden of mast cells defined by the presence of at least two 'B-findings' (Fig. 1 ). Of the 159 ISM patients in the Mayo Clinic series, 22 (14%) had SSM, 36 (23%) BMM, and the remaining 101 (63%) did not fit in with either category (ISM-other). SSM patients were significantly older than patients with BMM or ISM-other and more frequently presented with constitutional symptoms (45%) and anemia (55%). In contrast, BMM patients more frequently presented with MCMRS (86%), including anaphylaxis (78%).
Mast cell mediator (serum tryptase, and urine b prostaglandin F2a, histamine, and methylhistamine) levels were highest in SSM and lowest in BMM; there was a direct correlation between mast cell mediator levels and bone marrow mast cell burden. No cytogenetic abnormalities were seen. KITD816V and JAK2V617F were detected in 78 and 0% of ISM patients, respectively; KITD816V prevalence was not significantly different amongst the ISM subgroups.
Overall median survival in ISM was 198 months, which was not significantly different than that of the age-matched and sex-matched US control population ( patients had a significantly inferior survival (median 120 months) as compared with those with ISM-other (median 301 months) or BMM (not reached). In a multivariable analysis, advanced age was the primary determinant of inferior survival and accounted for the marked difference in survival between SSM and the other two groups. The overall risk of transformation to acute leukemia or ASM was low (<1 and 3%, respectively) but was significantly higher in SSM (18%).
Systemic mastocytosis with associated clonal hematological nonmast cell lineage disease
Although the pathophysiologic relationship between the 'systemic mastocytosis' and 'AHNMD' components of SM-AHNMD remains to be precisely delineated, lineage distribution studies [4, 22, 23] of the KITD816V mutation suggest clonal origination from a common stem cell; in some cases, the two components develop concomitantly [24] . Consistent with previous studies [25, 26] , we found SM-AHNMD to be the second most common subtype of systemic mastocytosis with 138 (40%) affected patients [27 ] . Of these, 123 (89%) had an associated myeloid neoplasm, whereas the remainder had lymphoma (n ¼ 7), myeloma (n ¼ 5), chronic lymphocytic leukemia (n ¼ 2), or primary amyloidosis (n ¼ 1). Of the patients with an associated myeloid malignancy, 55 (45%) had systemic mastocytosis-myeloproliferative neoplasms (SM-MPN), 36 (29%) systemic mastocytosis-chronic myelomonocytic leukemia (SM-CMML) and 28 (23%) systemic mastocytosis-myelodysplastic syndromes (SM-MDS).
We observed a high prevalence (34%) of prominent eosinophilia (!1.5 Â 10 9 /l) in SM-AHNMD patients, especially in those with SM-MPN. Clinical outcome was similar between SM-MPN patients with or without eosinophilia. Where tested, the prevalence of KITD816V, JAK2V617F, and Fip1-like-1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) mutations in systemic mastocytosis with prominent eosinophilia was 50, 8, and 63%, respectively. Abnormal karyotype was present in 18-41% of patients with SM-MPN/MDS/ CMML. JAK2V617F was mostly seen in SM-MPN.
Overall median survival in SM-AHNMD was 24 months (Fig. 2) . SM-MPN patients had a significantly longer median survival (31 months) as compared with patients with SM-CMML (15 months), SM-MDS (13 months), or systemic mastocytosis-acute leukemia (11 months). Leukemic transformation (13% overall) was seen more frequently in SM-MDS (29%) as compared with SM-MPN (11%) or SM-CMML (6%).
Aggressive systemic mastocytosis
Forty-one patients (12%) among the aforementioned Mayo Clinic cohort were classified as having ASM
[2 ]. Patients with ASM frequently displayed constitutional symptoms (60%), hepatosplenomegaly (50%), and lymphadenopathy (30%). As expected, patients with either ASM or SM-AHNMD were more likely to display severe anemia (hemoglobin <10 g/dl) and thrombocytopenia (platelets <100 Â 10 9 /l) and higher serum tryptase levels. An abnormal karyotype and KITD816V were noted in 20 and 82% of ASM patients, respectively. None of the patients with ASM harbored JAK2V617F. Overall median survival in ASM was 41 months (Fig. 2) , and leukemic transformation occurred in two patients (5%).
Mast cell leukemia
MCL was relatively rare among the 342 Mayo Clinic patients (1%; four patients) [2 ]; one patient had a concurrent chest wall mast cell sarcoma. MCL patients exhibited extensive bone marrow infiltration with mast cell (median bone marrow mast cell ¼ 75%; range ¼ 60-90%). The prognosis was dismal with a median survival of only 2 months (Fig. 2) .
Treatment: Mayo experience
Current therapy in systemic mastocytosis is suboptimal and includes observation alone or cytoreductive therapy in some instances (Fig. 3) [28] . Presence of MCMRS and organ dysfunction due to direct mast cell infiltration are main indications for treatment. Management of MCMRS includes avoidance of MCMRS-triggering factors and use of histamine antagonists and cromolyn sodium. Phototherapy is sometimes useful for skin disease, including urticaria pigmentosa. Refractory cases of both MCRMS and skin disease might sometimes require treatment with cytoreductive agents that are often used in the setting of ASM and SM-AHNMD. Cytoreductive agents in systemic mastocytosis include interferon alpha (IFNa) [29] [30] [31] [32] , 2-chlorodeoxyadenosine (2-CdA) [33] [34] [35] and imatinib mesylate [36] [37] [38] . Hydroxyurea is often utilized in the setting of SM-AHNMD.
We retrospectively studied 80 systemic mastocytosis patients who received a cytoreductive drug and were evaluable for response [39 ] . Forty-seven patients received IFNa with or without prednisone; the median weekly dose was 15 million units (MU) per week (range 3.5-30 MU per week), and the initial dose of prednisone ranged from 20 to 60 mg per day, with a slow tapering over weeks or months in some patients. In 40 evaluable patients, the overall response rate (ORR) was 53% (ISM and ASM 60%; SM-AHNMD 45%). Overall median duration of response was 12 months (range 1-67 months). Responses were not significantly different when comparing patients who did and did not receive prednisone. Absence of systemic mediator-related symptoms was significantly associated with inferior response to IFNa: 41 vs. 77%. Major toxicities included fatigue, depression, and thrombocytopenia.
Hydroxyurea use was largely restricted to SM-AHNMD patients (n ¼ 28) at a dose ranging from 500 mg every other day to 2000 mg per day. Twenty-six patients were evaluable for response with an ORR of 19%, reflected by control of thrombocytosis, leukocytosis, and/or hepatosplenomegaly. Median duration of response was 31.5 months (range 5-50 months); the major toxicity was myelosuppression.
Imatinib mesylate was administered to 27 systemic mastocytosis patients (FIP1L1-PDGFRA patients were excluded for this analysis); the median starting dose was 400 mg per day (range 100-400 mg per day), and the maintenance dose in responding patients ranged from 200 mg per day to 400 mg per day. In 22 evaluable patients, the ORR was 18% (ORR in ISM, ASM, and SM-AHNMD was 14, 50, and 9%, respectively), and median duration of response was 19.6 months (range 9-69 months). The majority (86%) of imatinib mesylate-treated patients were KITD816V positive; ORR in mutation-positive and mutation-negative patients was 17 and 33%, respectively. None of the six patients with systemic mastocytosis associated with eosinophilia responded to imatinib mesylate treatment; all patients were KITD816V positive. Major toxicities included diarrhea and peripheral edema; two patients developed interstitial pneumonitis.
2-CdA was administered to 26 patients (eight as firstline); the dose was 5 mg/m 2 per day or 0.13-0.17 mg/kg per day for 5 days as a 2-h intravenous (i.v.) infusion, and median number of treatment cycles was three (range 1-9). Treatment response was evaluable in 22 patients, and the ORR was 55% (ORR in ISM, ASM, and SM-AHNMD was 56, 50, and 55%, respectively). Median duration of response was 11 months (range 3-74 months). Presence of circulating immature myeloid cells was significantly associated with inferior response to 2-CdA (0 vs. 75%). Major toxicities were myelosuppression and infection. In the overall cohort (n ¼ 80), treatment response was not significantly different based on KITD816V or TET2 mutational status.
Investigational drug therapy
Although several drugs have shown in-vitro anti-KIT activity [40] [41] [42] [43] , the immediately most relevant in terms of clinical development include the tyrosine kinase inhibitors imatinib mesylate, nilotinib, dasatinib, and midostaurin (PKC412). Overall, imatinib mesylate has limited activity in unselected systemic mastocytosis patients; this is consistent with in-vitro experiments, which show that imatinib mesylate inhibits wild-type KIT and KIT mutants with transmembrane (F522C) and juxtamembrane (V559G and V560G) but not kinase (D816V or D814V) domain mutations [44] [45] [46] . Similarly, not all juxtamembrane mutations are sensitive to imatinib mesylate (e.g. V559I) [47] . Our data suggest that imatinib mesylate is of limited benefit in systemic mastocytosis therapy and is discordant with the results of another study [37] that suggested an ORR of 36% in KITD816V-positive systemic mastocytosis patients. In yet another study [38] of 20 systemic mastocytosis patients treated with imatinib mesylate, only one KITD816V-negative patient responded, whereas six other patients reported symptomatic improvement. Nilotinib is more potent than imatinib mesylate in its in-vitro anti-breakpoint cluster regionabelson (BCR-ABL) activity but appears to be similarly ineffective against KITD816V [48] . Another study [49] , however, suggested a more potent activity of nilotinib against KITD816V.
Dasatinib has shown potent anti-KIT activity in mast cells and leukemia cell lines with different KIT mutants including D816V [50, 51] . Furthermore, dasatinib might synergize with both PKC412 and chemotherapy in this regard [52, 53, 54 ]. In the largest study of dasatinib therapy in systemic mastocytosis [55 ] , the drug was given at a starting dose of 70 mg oral (p.o.) twice daily b.i.d. to 33 systemic mastocytosis patients: 18 indolent, nine aggressive and six with associated nonmast cell myeloid neoplasm. Two (6%) patients, both of whom were D816V negative, achieved complete remission. Nine (27%) patients experienced symptomatic improvement. However, grade 3 toxicities were observed in 19 (58%) patients. In another study [56 ] , four systemic mastocytosis patients (all KITD816V positive; two with ASM, one SM-AHNMD, and one ISM) were treated with dasatinib at a dose ranging from 50 to 100 mg b.i.d. Two patients (one each with ASM and SM-AHNMD) had a major response, which in the case of the SM-AHNMD patient was accompanied by a decrease in the bone marrow mast cell burden. Both responders experienced an initial exacerbation of MCMRS and rash lasting several days before the benefits of dasatinib therapy became evident.
PKC412 has in-vitro activity against cells transformed with kinase domain KIT mutants (D816Y and D816V) [57, 58] , and treatment of a patient with MCL who harbored KITD816V resulted in transient clinical benefit [59] . Preliminary data from a clinical trial in systemic mastocytosis have been presented [60] , wherein p.o. PKC412 was administered at a daily dose of 100 mg b.i.d. to 15 systemic mastocytosis patients, nine of whom had associated nonmast cell myeloid neoplasm. KITD816V mutational frequency was 60%. There was some evidence of clinical activity in 11 (73%) patients, including increase in hemoglobin (n ¼ 1) and reduction of ascites (n ¼ 2) or pleural effusion (n ¼ 2). In four patients, the bone marrow mast cell burden was reported to have decreased from 50-60% to 10-15%. Untoward reactions of PKC412 in the particular study included nausea and vomiting, anemia, and thrombocytopenia.
Conclusion
Specific treatment in systemic mastocytosis is indicated only in the presence of symptomatic disease. In general, patients with nonsmoldering variant ISM should expect a normal life expectancy and avoid cytoreductive therapy. Cladribine is a reasonable first-line drug therapy for ASM, but IFNa can also be effective. Treatment strategies in SM-AHNMD patients should be directed at the nonmast cell lineage component of the disease unless accompanied by a high mast cell burden. Anti-KIT therapy in KIT D816V-positive systemic mastocytosis patients has so far not been successful, and it is reasonable to consider targeting other signaling pathways that might contribute to the pathogenesis of the disease. Examples include Janus kinase/signal transducer and activator of transcription (JAK-STAT) and phosphatidylinositol-3-kinase and protein kinase B (PI3K-Akt).
